Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
about
The metabolic vascular syndrome - guide to an individualized treatmentHeart Failure: a Major Cardiovascular Complication of Diabetes MellitusSpotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to dateFrom ARB to ARNI in Cardiovascular ControlUpdate on RAAS Modulation for the Treatment of Diabetic Cardiovascular DiseaseResearch into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial.Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure.Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure.Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.Angiotensin-Neprilysin Inhibition as a Paradigm for All?Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan.Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC).Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes.Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology.Still sour about lactic acidosis years later: role of metformin in heart failure.Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial.Age affects the prognostic impact of diabetes in chronic heart failure.[Acute and chronic heart failure].Perspective Review: Type 2 Diabetes and Readmission for Heart Failure.The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.Sacubitril/Valsartan (LCZ696) in Heart FailurePrognostic Impact of Fasting Plasma Glucose on Mortality and Re-Hospitalization in Patients with Acute Heart Failure
P2860
Q26767142-51EBE2F1-E2E1-4473-B1EE-683620EA36EEQ28066310-3E8C20E4-CBAB-4F2F-83C9-178B5FF97DC7Q28070064-642AEAC1-1CFA-4B96-80F8-6A621FDEB947Q28073372-B93E623B-E53C-4941-ABC0-1A872FC47753Q28077454-16E5CC4C-7C1B-4DCE-8A1B-8771912F5D46Q37097189-77F009F9-A91D-40C9-AD19-A85979ABF9B8Q38374511-3AE29F23-1106-4DA6-9C73-DCB016A59559Q38604382-5EBAC657-50DF-41C1-8CBD-92C383E9F506Q38625516-978AD14F-5C3C-4D20-B3C4-2C2547192FA0Q38731859-F3D6FC1E-DB3A-450C-9E1D-2CBFBA9330D9Q38790076-5BB0A438-68CF-4FF0-A6CE-788DFD1F2F17Q38885540-997E3E37-5D47-49F8-8662-E54D592B5ED0Q38982213-8941F9F6-1706-4A0E-A103-0ACF488FEDAEQ39011741-7987CD7E-9777-4EB4-B44C-6CE5F48EF0E5Q41549636-9C631296-EEE4-4170-A73C-A3F216F80A13Q41686268-091656F1-89C0-4689-B472-F3FB5CDE4E44Q42373826-95728962-EB90-4FEF-942B-E745E9081592Q47146712-985CCF77-BD2B-4CC3-BE8A-A881A8E242D2Q47642528-ABB697CE-A005-4DA7-B7EA-18143D2BD5B0Q48134998-0177B8F8-D8DB-4B6C-887C-5584C05EB06CQ48141985-CC5637D8-9285-4C97-83C2-5F9F2BE4C906Q49834040-308677D1-AA13-4CBA-9BE8-7C2E40D76AC8Q50128096-9F3AF637-9DBC-4F12-B094-FB17A3143BD9Q52821448-BE9901B1-1294-405A-8772-2863C1FB6711Q55040628-CD837FCB-D477-419F-A8E8-B159D0C47FA0Q55078568-B4BE2C55-8780-41BD-AFB9-0578B5FCE926Q57396137-682207F7-1287-4450-BE22-0F79D9D8494DQ58763921-6BA29890-8580-407F-B609-C1E1581FD8CF
P2860
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Risk Related to Pre-Diabetes M ...... rbidity in Heart Failure Trial
@ast
Risk Related to Pre-Diabetes M ...... rbidity in Heart Failure Trial
@en
type
label
Risk Related to Pre-Diabetes M ...... rbidity in Heart Failure Trial
@ast
Risk Related to Pre-Diabetes M ...... rbidity in Heart Failure Trial
@en
prefLabel
Risk Related to Pre-Diabetes M ...... rbidity in Heart Failure Trial
@ast
Risk Related to Pre-Diabetes M ...... rbidity in Heart Failure Trial
@en
P2093
P2860
P50
P1476
Risk Related to Pre-Diabetes M ...... rbidity in Heart Failure Trial
@en
P2093
Adel R Rizkala
Akshay S Desai
Bela Merkely
Felipe Martinez
Iain Squire
Jean L Rouleau
José Silva Cardoso
Karl Swedberg
Martin P Lefkowitz
Milton Packer
P2860
P356
10.1161/CIRCHEARTFAILURE.115.002560
P577
2016-01-01T00:00:00Z